naturalnews.com printable article

Originally published January 26 2005

Painkiller Bextra might lead to heart attack risk when combined with aspirin

by Mike Adams, the Health Ranger, NaturalNews Editor

New studies say that the popular painkiller Bextra, when taken with aspirin, seems to significantly increase a patient's risk of heart attack. Bextra is among several new painkillers that are undergoing intense scrutiny from regulators because the drugs have been implicated in some heart attack cases. Vioxx has been taken off the market, and the license for Celebrex is currently under review.


Combining aspirin (search) with the painkiller Bextra (search) may magnify the heart-related risks associated with Bextra and similar drugs. They suggest that combining Bextra with aspirin may increase the risk of blood clots that could trigger a heart attack or stroke. Last month, the FDA added anew warning to Bextra, which states that Bextra should not be used in patients undergoing heart bypass surgery after a clinical trial showed an increase in heart problems in bypass patients using Bextra. A similar drug, Vioxx (search), was removed from the market in September 2004 because of an increase in heart attacks and stroke in patients taking the drug for at least 18 months. A third, similar drug, Celebrex, was linked to heart attacks last month as well. Like the other Cox-2 inhibitors, Vioxx and Celebrex (search), it was designed to treat arthritis and other painful conditions. Older drugs like ibuprofen (search) and naproxen (search) treat pain and inflammation by blocking two enzymes, Cox-1 and Cox-2. In the studies, which appear in the Jan. 17 issue of Circulation: Journal of the American Heart Association, researchers examined some potential mechanisms behind the increase in heart problems associated with Cox-2 inhibitors. In the first study, researchers studied the effects of Bextra and aspirin on hardening of the arteries (atherosclerosis) in mice prone to the condition. They found that low-dose aspirin slowed the development of atherosclerosis in the mice, but it seemed ineffective once the disease was established. "We were amazed," says researcher Karine Egan, PhD, of the University of Pennsylvania, in a news release. By adding a Cox-2 inhibitor, researchers say the beneficial effects of aspirin may be lost by tipping the balance in favor of the Cox-1 enzyme.



All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml